Clinical Trial Update: Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating anakinra to prevent cytokine release syndrome and neurotoxicity in patients with B-cell non-Hodgkin lymphoma receiving CD19-targeted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-10-23